Ashwagandha and Breast Cancer: What the Quality-of-Life Research Really Shows
One analysis ranked ashwagandha first for quality of life in breast cancer. It rests on one non-randomized trial. What it found and what it can’t tell you.
One analysis ranked ashwagandha first for quality of life in breast cancer. It rests on one non-randomized trial. What it found and what it can’t tell you.
Ashwagandha trials report modest LDL and triglyceride shifts. What that is worth in midlife, when the lipid profile changes with declining estrogen.
Perimenopausal hair thinning is largely androgenic and estrogen-driven. What two placebo-controlled ashwagandha hair trials measured, and their limits.
Ashwagandha does not balance hormones, work instantly, or suit everyone. The most common marketing claims, checked against what the research shows.
After menopause the hormonal driver is gone but cortisol, sleep and bone loss remain. What changes about taking ashwagandha for women over 60.
Perimenopausal headaches track estrogen withdrawal, sleep debt and stress load together. What the ashwagandha inflammation research suggests, and its limits.
Cortisol shifts fat to the midsection, and perimenopause amplifies it. What the ashwagandha weight trials actually measured, and how large the effect was.
Maca is non-hormonal and libido-focused, ashwagandha works through cortisol and stamina. A side-by-side look at the perimenopause evidence for each.
Perimenopausal joint pain tracks declining estrogen and rising inflammation. Where ashwagandha’s anti-inflammatory data applies, and where it does not.
The stress response runs through the HPA axis, and ashwagandha appears to blunt its output. How the adaptogenic mechanism is thought to work.
Withanolide absorption, half-life and clearance shape dosing and timing. What is known about how the body actually processes ashwagandha extract.
The recent ashwagandha literature is small, mostly short, and rarely perimenopause-specific. What the newest trials add, and what the gaps still are.